Evidence map›Paper›PMID 39792384›Full record

ArticleJAMA network open2025

Attributable Risk and Consequences of Bone Mineral Density Deficits in Childhood Cancer Survivors.

Chelsea G Goodenough, Jessica L Baedke, Angela M Delaney, Carmen L Wilson, Tara M Brinkman, Cindy Im, Megan E Ware, Hiroto Inaba, Karen L Clark, Gregory T Armstrong and 11 more

Abstract read
In one paragraph

Article in JAMA network open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Chelsea G GoodenoughDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Jessica L BaedkeDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Angela M DelaneyEndocrinology Department, St Jude Children's Research Hospital, Memphis, Tennessee.
Carmen L WilsonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Tara M BrinkmanDepartment of Psychology and Biobehavioral Sciences, St Jude Children's Research Hospital, Memphis, Tennessee.
Cindy ImDepartment of Pediatrics, University of Minnesota, Minneapolis.
Megan E WareDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Hiroto InabaOncology Department, St Jude Children's Research Hospital, Memphis, Tennessee.
Karen L ClarkCenter for Advanced Practice, St Jude Children's Research Hospital, Memphis, Tennessee.
Gregory T ArmstrongDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Daniel A MulrooneyDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Ching-Hon PuiOncology Department, St Jude Children's Research Hospital, Memphis, Tennessee.
Daniel M GreenOncology Department, St Jude Children's Research Hospital, Memphis, Tennessee.
Thomas E MerchantDepartment of Radiation Oncology, St Jude Children's Research Hospital, Memphis, Tennessee.
Deo Kumar SrivastavaBiostatistics Department, St Jude Children's Research Hospital, Memphis, Tennessee.
Yutaka YasuiDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Melissa M HudsonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Leslie L RobisonDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Sue C KasteDiagnostic Imaging Department, St Jude Children's Research Hospital, Memphis, Tennessee.
Kirsten K NessDepartment of Epidemiology and Cancer Control, St Jude Children's Research Hospital, Memphis, Tennessee.
Wassim ChemaitillyDivision of Endocrinology, Department of Pediatrics, University of Pittsburgh School of Medicine, Pittsburgh, Pennsylvania.

Funding

Viral Vector Technology (VVTSR)P30CA021765 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Shondra Michelle Miller · 1985 to 2026
$166.9M
The St. Jude Lifetime CohortU01CA195547 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI HUDSON, MELISSA M, NESS, KIRSTEN KIMBERLIE · 2015 to 2024
$14.9M
Training in Pediatric Cancer Survivorship Outcomes and InterventionsT32CA225590 · NCI · ST. JUDE CHILDREN'S RESEARCH HOSPITAL · PI Kevin R Krull · 2018 to 2026
$2.4M
NCI NIH HHS P30 CA021765NCI NIH HHS T32 CA225590NCI NIH HHS U01 CA195547
6 · The paper itself

Abstract

Importance: Data characterizing the severity and changing prevalence of bone mineral density (BMD) deficits and associated nonfracture consequences among childhood cancer survivors decades after treatment are lacking. Objective: To evaluate risk for moderate and severe BMD deficits in survivors and to identify long-term consequences of BMD deficits. Design, Setting, and Participants: This cohort study used cross-sectional and longitudinal data from the St Jude Lifetime (SJLIFE) cohort, a retrospectively constructed cohort with prospective follow-up. Participants in SJLIFE are adult survivors of childhood cancer who were diagnosed between 1962 and 2012 and survived 5 years or more from diagnosis. Data were collected from November 2007 to June 2020 and analyzed from January 2021 to November 2023. Exposures: Childhood cancer therapy exposures, clinically ascertained comorbid conditions, substance use, and sedentary lifestyle. Main Outcomes and Measures: BMD was evaluated using lumbar quantitative computed tomography and classified by age- and sex-specific z scores with moderate (≤-1 SD) or severe (≤-2 SD) deficits. Multivariable logistic regression estimated odds ratios (ORs), attributable fractions (AFs), and associations between BMD deficits and long-term sequelae (social, functional, and quality of life [QOL]). Results: Among 3919 five-year survivors (median [range] age, 31.7 [18.0-69.9] years; 2063 [52.6%] male; 105 [2.7%] Hispanic, 607 [15.5%] non-Hispanic Black, and 3153 [80.4%] non-Hispanic White), prevalence of moderate or severe BMD deficits were 21.7% (95% CI, 20.4%-23.0%) and 6.9% (95% CI, 6.1%-7.7%), respectively. Treatment exposures (including age at diagnosis), comorbid conditions, and smoking and sedentary behavior explained 18.5%, 10.2%, and 7.0% of moderate and 55.4%, 51.1%, and 9.9% of severe deficits. Severe deficits were associated with 30 Gy or greater cranial radiotherapy (CRT) (OR, 5.22; 95% CI, 3.74-7.30; AF, 33.0%), testicular or pelvic radiation (OR, 1.70, 95% CI, 1.19-2.44; AF, 11.5%), hypogonadism (OR, 3.27, 95% CI, 2.35-4.55; AF, 25.1%), growth hormone deficiency (OR, 5.28, 95% CI, 3.68-7.56; AF, 26.0%), smoking (OR, 1.71, 95% CI, 1.21-2.43; AF, 6.7%), and sedentary behavior (OR, 2.06, 95% CI, 1.15-3.69; AF, 6.2%). CRT exposure increased risk for declining BMD (OR, 2.94, 95% CI, 1.46-5.91; AF, 8.8%). Survivors with deficits were less likely to live alone and to be employed and more likely to require personal care assistance and to report depressive symptoms and poor QOL. Conclusions and Relevance: While treatment exposures were associated with long-term BMD deficits, modifiable risk factors, including smoking, sedentary behavior, hypogonadism, and growth hormone deficiency, suggest feasible targets for intervention.

Indexed as

Bone DensityCancer SurvivorsAdolescentAdultChildCross-Sectional StudiesFemaleHumansLongitudinal StudiesMaleMiddle AgedNeoplasmsQuality of LifeRetrospective StudiesRisk FactorsYoung Adult

Identifiers

PMID39792384
PMCPMC11724346

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.